National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 5) (PB 40 of 2014)

Link to law: https://www.comlaw.gov.au/Details/F2014L00577

 
PB 40 of 2014
National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 5)
 
National Health Act 1953
___________________________________________________________________________
 
 
I, KIM BESSELL, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.
Dated   15 May 2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KIM BESSELL
Assistant Secretary
Pharmaceutical Access Branch
Pharmaceutical Benefits Division
Department of Health
___________________________________________________________________________
 
 
1       Name of Instrument
 
(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No.5).
 
(2)                This Instrument may also be cited as PB 40 of 2014.
 
2              Commencement
This Instrument commences on 1 June 2014.
3              Amendments to PB 116 of 2010
Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).
 
 
Schedule 1       Amendments
[1]           Schedule 1, entry for Mycophenolic Acid, in the form Capsule containing mycophenolate mofetil 250 mg, brand name Imulate
omit
[2]           Schedule 1, entry for Mycophenolic Acid, in the form Tablet containing mycophenolate mofetil 500 mg, brand name Imulate
omit
[3]           Schedule 3, entry for Plerixafor [Circumstances Code: 4549]
omit from the column headed “Circumstances and Purposes”:
Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per microlitre on the day of planned collection; OR
substitute:
Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per millilitre or less than 10 million per litre on the day of planned collection; OR
[4]           Schedule 3, entry for Plerixafor [Circumstances Code: 4550]
omit from the column headed “Circumstances and Purposes”:
Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per microlitre on the day of planned collection; OR
substitute:
Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per millilitre or less than 10 million per litre on the day of planned collection; OR
 
 
Read Entire Law on www.comlaw.gov.au